

Philippe Pouletty, MD, 46, is chairman of France Biotech, the French Biotech Industry Association, of the Strategic Council for Innovation, Vice-chairman of Europabio, the European biotech industry association, a member of the Conseil pour l'Attractivité de la France and a general partner of Truffle Venture, a €100 million venture capital fund based in Paris focusing on starting companies resulting from the spin off of late stage technologies acquired from large companies or research institutes. He is the founder of three successful biotechnology companies in North America and Europe, SangStat, Conjuchem and DrugAbuse Sciences and a board member of Neovacs, Innate Pharma and BMD. Dr Pouletty triggered several government initiatives in France, including the 1999 SAS law to simplify the management of novel companies, the "Plan Biotech 2002" to boost the French biotechnology industry and the Young Innovative Enterprise status (JEI) recently implemented in France. He is the founder and president of the Strategic Council for Innovation, which provides independent advice to the French government on innovation and research policy. He is a Chevalier de la Légion d'Honneur, 1999 laureate of the American Liver Foundation and the inventor of 20 patents in the healthcare and biotechnology fields.